PPP versus PPPP: What is Wrong in Denmark?

Research output: Contribution to conferencePaperResearch

61 Downloads (Pure)


This paper addresses Public Private Partnerships (PPP) and Pharmaceutical Public
Private Partnerships (PPPP) in Denmark or the lack of PPP(P)’s in Denmark. It
would seem, that the market for PPP(P)’s in Denmark is either very small, nonexisting or it might be disturbed by several factors: legal and political, business and structural. Besides pointing out some relevant key factors preventing PPP’s, the paper presents some new information: It is not only in the infrastructure industry that the lack of PPP is significant. The idea of establishing PPPP’s between the private pharmaceutical industry and the university sector is also problematic. This paper identifies that the creation of a common PPP business case is difficult in Denmark in both the infrastructure and the pharmaceutical industry.
Original languageEnglish
Publication dateJun 2013
Number of pages16
Publication statusPublished - Jun 2013
EventPublic-Private Partnership Conference Series CBS-Sauder-Monash 2013 - Sauder School of Business, The University of British Columbia Vancouver, BC , Vancouver, Canada
Duration: 13 Jun 201314 Jun 2013
Conference number: 2


ConferencePublic-Private Partnership Conference Series CBS-Sauder-Monash 2013
LocationSauder School of Business, The University of British Columbia Vancouver, BC
Internet address


  • Public private partnership
  • Pharmaceutical public private partnership
  • Market disturbance
  • Business case
  • Legal obstacles
  • Joint utility
  • Self-optimizing
  • Contract law

Cite this